154 related articles for article (PubMed ID: 21719255)
41. A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease.
Kozor R; Callaghan F; Tchan M; Hamilton-Craig C; Figtree GA; Grieve SM
J Cardiovasc Magn Reson; 2015 Feb; 17(1):22. PubMed ID: 25890002
[TBL] [Abstract][Full Text] [Related]
42. Tei-index in symptomatic patients with primary and secondary mitral regurgitation.
Bruch C; Schmermund A; Dagres N; Katz M; Bartel T; Erbel R
Int J Cardiovasc Imaging; 2002 Apr; 18(2):101-10. PubMed ID: 12108905
[TBL] [Abstract][Full Text] [Related]
43. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy.
Messalli G; Imbriaco M; Avitabile G; Russo R; Iodice D; Spinelli L; Dellegrottaglie S; Cademartiri F; Salvatore M; Pisani A
Radiol Med; 2012 Feb; 117(1):19-28. PubMed ID: 21744250
[TBL] [Abstract][Full Text] [Related]
44. Tissue Doppler imaging in Fabry disease.
Pieroni M; Chimenti C; Russo A; Russo MA; Maseri A; Frustaci A
Curr Opin Cardiol; 2004 Sep; 19(5):452-7. PubMed ID: 15316452
[TBL] [Abstract][Full Text] [Related]
45. Comparison of Cardiac Magnetic Resonance Imaging and Echocardiography in Assessment of Left Ventricular Hypertrophy in Fabry Disease.
Hazari H; Belenkie I; Kryski A; White JA; Oudit GY; Thompson R; Fung T; Dehar N; Khan A
Can J Cardiol; 2018 Aug; 34(8):1041-1047. PubMed ID: 29935990
[TBL] [Abstract][Full Text] [Related]
46. Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy.
Krämer J; Bijnens B; Störk S; Ritter CO; Liu D; Ertl G; Wanner C; Weidemann F
PLoS One; 2015; 10(11):e0140627. PubMed ID: 26600044
[TBL] [Abstract][Full Text] [Related]
47. [Prognostic value of the myocardial performance (Tei) index in patients with chronic heart failure].
Larina VN; Bart BIu; Dergunova EN; Alekhin MN
Kardiologiia; 2013; 53(11):37-44. PubMed ID: 24654433
[TBL] [Abstract][Full Text] [Related]
48. Can myocardial performance index predict the presence of silent ischemia in asymptomatic type 2 diabetic patients?
Al-Daydamony MM; El-Tahlawi MA; Shawky A
Echocardiography; 2016 Dec; 33(12):1823-1827. PubMed ID: 27677770
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of myocardial function using the Tei index in patients with Kawasaki disease.
Ajami G; Borzouee M; Amoozgar H; Ashnaee F; Kashef S; Nesar MS; Nesar MS
Cardiol Young; 2010 Feb; 20(1):44-8. PubMed ID: 20018134
[TBL] [Abstract][Full Text] [Related]
50. Late gadolinium enhancement image masquerading as hypertrophic cardiomyopathy in Fabry disease receiving enzyme replacement therapy.
Yano T; Oshima H; Miki T; Tanaka M; Muranaka A; Osanami A; Takahashi F; Miura T
Int J Cardiol; 2016 Jan; 203():136-7. PubMed ID: 26512827
[No Abstract] [Full Text] [Related]
51. Left ventricular noncompaction in a patient with fabry disease: overdiagnosis, morphological manifestation of fabry disease or two unrelated rare conditions in the same patient?
Azevedo O; Gaspar P; Sá Miranda C; Cunha D; Medeiros R; Lourenço A
Cardiology; 2011; 119(3):155-9. PubMed ID: 21952291
[TBL] [Abstract][Full Text] [Related]
52. [Role of cardiac magnetic resonance in cardiac involvement of Fabry disease].
Serra VM; Barba MA; Torrá R; Pérez De Isla L; López M; Calli A; Feltes G; Torras J; Valverde V; Zamorano JL
Med Clin (Barc); 2010 Sep; 135(7):300-5. PubMed ID: 20605170
[TBL] [Abstract][Full Text] [Related]
53. MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease.
Koeppe S; Neubauer H; Breunig F; Weidemann F; Wanner C; Sandstede J; Machann W; Hahn D; Köstler H; Beer M
Int J Cardiol; 2012 Sep; 160(1):53-8. PubMed ID: 21463907
[TBL] [Abstract][Full Text] [Related]
54. [Evaluation of left ventricular dysfunction by Tei index in neonates with hypoxemia].
Wang L; Zhou Y; Li MX
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Feb; 13(2):111-4. PubMed ID: 21342618
[TBL] [Abstract][Full Text] [Related]
55. [Left ventricular Tei-index for evaluation of cardiac function in hypertensive patients with left ventricular hypertrophy after radiochemotherapy].
Huang ZQ; Li T
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jun; 38(6):761-764. PubMed ID: 29997102
[TBL] [Abstract][Full Text] [Related]
56. Fabry disease in cardiology practice: Literature review and expert point of view.
Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of left ventricular global function, using Doppler myocardial performance index in patients with systemic hypertension.
Sarkar H; Siddique MA; Haque KM; Ahmed CM; Mahmood M; Bhattacharjee B; Debnath RC
Mymensingh Med J; 2008 Jul; 17(2 Suppl):S65-71. PubMed ID: 18946455
[TBL] [Abstract][Full Text] [Related]
58. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.
Beer M; Weidemann F; Breunig F; Knoll A; Koeppe S; Machann W; Hahn D; Wanner C; Strotmann J; Sandstede J
Am J Cardiol; 2006 May; 97(10):1515-8. PubMed ID: 16679096
[TBL] [Abstract][Full Text] [Related]
59. Tei index (myocardial performance index) and cardiac biomarkers in dogs with parvoviral enteritis.
Kocaturk M; Martinez S; Eralp O; Tvarijonaviciute A; Ceron J; Yilmaz Z
Res Vet Sci; 2012 Feb; 92(1):24-9. PubMed ID: 21074228
[TBL] [Abstract][Full Text] [Related]
60. Role of cardiac imaging in Anderson-Fabry cardiomyopathy.
Serra W; Marziliano N
Cardiovasc Ultrasound; 2019 Jan; 17(1):1. PubMed ID: 30674321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
